Non-Small-Cell Lung Cancer | Unmet Need | US/EU | 2016
Metastatic squamous-cell NSCLC is an incurable disease associated with a dismal 5 year OS of <5%; treatments delivering improvements to survival are therefore a key treatment goal in this disease. Despite recent approvals of Portrazza, Opdivo and Keytruda for metastatic squamous-cell NSCLC, surveyed oncologists highlight that novel therapies with improved clinical efficacy are still an area of high unmet need. This report investigates key drivers of prescribing in squamous-cell NSCLC, and identifies key areas of unmet need in the indication.
Related Market Assessment Reports
Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
